About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 448 record(s)
Req # A-2021-000401
The list of all suppliers or importers of protective masks or medical masks (surgical and intervention masks) containing nanoform graphene in Canada for the period of January 1, 2020 to January 1, 2021.Organization: Health Canada
September 2021
Req # A-2021-000403
Adverse Reaction Reports (AERs) for CANCIDAS. Report numbers: 000725996, E2B_02546063, E2B_02437067, E2B_01728486, E2B_02197588, E2B_02088620, 000520787, 000715061, E2B_01460407, E2B_01728486.Organization: Health Canada
September 2021
Req # A-2021-000418
Adverse Reaction Reports (AERs). Report numbers: E2B_03382007, E2B_03382008, 000934253, 000928734, E2B_03566993.Organization: Health Canada
September 2021
Req # A-2021-000452
Looking for data of youth (younger than 18) who are held in mental health facilities involuntarily. Province: All (Focus on Ontario) Date Range: Annual Data from 2010 - 2020.Organization: Health Canada
September 2021
Req # A-2021-000453
Adverse Reaction Reports (AERs) for Celexa® (citalopram). Report numbers: 0922916, E2B_03373326, 922193, 930241, E2B_03419846, 924621, 925645, E2B_03428005, E2B_03452345, E2B_03443817, 926929 E2B_03443807, E2B_03457500.Organization: Health Canada
September 2021
Req # A-2021-000455
Adverse Reaction Reports (AERs) for Cipralex. Report numbers: 923684, E2B_03452280, E2B_03459529, E2B_03464446, E2B_03468295, 927034, 926097, E2B_03468309. (AER) for Trintellix. Report number: 924115.Organization: Health Canada
September 2021
Req # A-2021-000463
Adverse Reaction Reports (AERs) for pms-Azithromycin. Report numbers: E2B_03223431, E2B_03223433, E2B_03223464, E2B_03535725, E2B_03223478, E2B_03574940, E2B_03223466, E2B_03223436, E2B_03581960, E2B_03535703, E2B_03584539. AER for pms-Amiodarone. Report number: 000918002. AER for Trandate. Report number: E2B_01448607. AER for pdp-Hydrocodone. Report number: 000914286.Organization: Health Canada
September 2021
Req # A-2021-000467
Adverse Drug Reaction (ADR) for Gallium Citrate (Ga-67). Report number: 000941334.Organization: Health Canada
September 2021
Req # A-2021-000468
Adverse Drug Reaction (ADR) for ALEMTUZUMAB. Report number: E2B_03391205.Organization: Health Canada
September 2021
Req # A-2021-000480
The department's Corporate Risk Profile (sometimes entitled Departmental Risk Profile or the Integrated Risk Profile).Organization: Health Canada
September 2021